Evaluation and Treatment of Patients With Hypercortisolism: A Review.
暂无分享,去创建一个
[1] I. Bancos,et al. Cardiovascular risk and mortality in patients with active and treated hypercortisolism. , 2020, Gland surgery.
[2] B. S. Miller,et al. Adrenal Crisis. , 2019, The New England journal of medicine.
[3] S. Taler,et al. New-onset resistant hypertension in a newly diagnosed prostate cancer patient. , 2019, American journal of hypertension.
[4] I. Bryngelsson,et al. Overall and Disease-Specific Mortality in Patients With Cushing Disease: A Swedish Nationwide Study. , 2019, The Journal of clinical endocrinology and metabolism.
[5] H. Raff,et al. Assay-Specific Spurious ACTH Results Lead to Misdiagnosis, Unnecessary Testing, and Surgical Misadventure—A Case Series , 2019, Journal of the Endocrine Society.
[6] F. Kober,et al. Cushing Syndrome Is Associated With Subclinical LV Dysfunction and Increased Epicardial Adipose Tissue. , 2018, Journal of the American College of Cardiology.
[7] I. Chiodini,et al. Cardiovascular mortality in patients with subclinical Cushing. , 2018, Annales d'endocrinologie.
[8] Viju Raghupathi,et al. An Empirical Study of Chronic Diseases in the United States: A Visual Analytics Approach to Public Health , 2018, International journal of environmental research and public health.
[9] Weihong Guo,et al. Effect of hypercortisolism on bone mineral density and bone metabolism: A potential protective effect of adrenocorticotropic hormone in patients with Cushing’s disease , 2017, The Journal of international medical research.
[10] H. Stoddart. Low dehydroepiandrosterone sulphate: a sensitive and specific test for the detection of subclinical hypercortisolism in adrenal incidentalomas , 2017, Annals of clinical biochemistry.
[11] A. Comlekçi,et al. Interference in ACTH immunoassay negatively impacts the management of subclinical hypercortisolism , 2017, Endocrine.
[12] A. Lowery,et al. Posterior retroperitoneoscopic adrenal surgery for clinical and subclinical Cushing’s syndrome in patients with bilateral adrenal disease , 2017, Langenbeck's Archives of Surgery.
[13] M. Bufi,et al. Clinical Benefits of Unilateral Adrenalectomy in Patients with Subclinical Hypercortisolism Due to Adrenal Incidentaloma: Results from a Single Center , 2017, High Blood Pressure & Cardiovascular Prevention.
[14] W. Inder. Towards a universally accepted definition of subclinical Cushing's syndrome – subclinical autonomous hypercortisolism , 2017, Clinical endocrinology.
[15] C. Lombardi,et al. Outcome of adrenalectomy for subclinical hypercortisolism and Cushing syndrome , 2017, Surgery.
[16] A. Pontecorvi,et al. Factors predicting the duration of adrenal insufficiency in patients successfully treated for Cushing disease and nonmalignant primary adrenal Cushing syndrome , 2017, Endocrine.
[17] Fares Alahdab,et al. THERAPY OF ENDOCRINE DISEASE: Improvement of cardiovascular risk factors after adrenalectomy in patients with adrenal tumors and subclinical Cushing's syndrome: a systematic review and meta-analysis. , 2016, European journal of endocrinology.
[18] A. Tabarin,et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. , 2016, European journal of endocrinology.
[19] Niki Karavitaki,et al. Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study. , 2016, The lancet. Diabetes & endocrinology.
[20] I. Chiodini,et al. Adrenalectomy reduces the risk of vertebral fractures in patients with monolateral adrenal incidentalomas and subclinical hypercortisolism. , 2016, European journal of endocrinology.
[21] Douglas B. Evans,et al. Cosyntropin stimulation testing on postoperative day 1 allows for selective glucocorticoid replacement therapy after adrenalectomy for hypercortisolism: Results of a novel, multidisciplinary institutional protocol. , 2016, Surgery.
[22] S. Tsagarakis,et al. Biochemical and clinical benefits of unilateral adrenalectomy in patients with subclinical hypercortisolism and bilateral adrenal incidentalomas. , 2015, European journal of endocrinology.
[23] Martin Reincke,et al. Subclinical hypercortisolism: a state, a syndrome, or a disease? , 2015, European journal of endocrinology.
[24] A. Lacroix,et al. Multiple aberrant hormone receptors in Cushing's syndrome. , 2015, European journal of endocrinology.
[25] A. Tabarin,et al. Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. , 2015, The Journal of clinical endocrinology and metabolism.
[26] L. Nieman. Update on subclinical Cushing's syndrome , 2015, Current opinion in endocrinology, diabetes, and obesity.
[27] A. Fassina,et al. An analysis of different therapeutic options in patients with Cushing's syndrome due to bilateral macronodular adrenal hyperplasia: a single‐centre experience , 2015, Clinical endocrinology.
[28] O. Dekkers,et al. Management of endocrine disease: Mortality remains increased in Cushing's disease despite biochemical remission: a systematic review and meta-analysis. , 2015, European journal of endocrinology.
[29] F. Beuschlein,et al. Time to recovery of adrenal function after curative surgery for Cushing's syndrome depends on etiology. , 2015, The Journal of clinical endocrinology and metabolism.
[30] D. Nitti,et al. Systematic review of surgical treatment of subclinical Cushing's syndrome , 2015, The British journal of surgery.
[31] H. Raff,et al. Urine free cortisol in the diagnosis of Cushing's syndrome: is it worth doing and, if so, how? , 2015, The Journal of clinical endocrinology and metabolism.
[32] A. Comlekçi,et al. DHEAS for the prediction of subclinical Cushing’s syndrome: perplexing or advantageous? , 2015, Endocrine.
[33] Jing Shen,et al. Nonconformity in the clinical practice guidelines for subclinical Cushing's syndrome: which guidelines are trustworthy? , 2014, European journal of endocrinology.
[34] M. Bradburn,et al. Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas. , 2014, The Journal of clinical endocrinology and metabolism.
[35] F. Beuschlein,et al. Adrenal function after adrenalectomy for subclinical hypercortisolism and Cushing's syndrome: a systematic review of the literature. , 2014, The Journal of clinical endocrinology and metabolism.
[36] R. Golfieri,et al. Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing's syndrome: a 15-year retrospective study. , 2014, The lancet. Diabetes & endocrinology.
[37] S. Fried,et al. Deconstructing the roles of glucocorticoids in adipose tissue biology and the development of central obesity. , 2014, Biochimica et biophysica acta.
[38] E. Horváth-Puhó,et al. Multisystem morbidity and mortality in Cushing's syndrome: a cohort study. , 2013, The Journal of clinical endocrinology and metabolism.
[39] D. Nitti,et al. Adrenalectomy may improve cardiovascular and metabolic impairment and ameliorate quality of life in patients with adrenal incidentalomas and subclinical Cushing's syndrome. , 2012, Surgery.
[40] G. Gamble,et al. Mortality and morbidity in Cushing’s syndrome in New Zealand , 2011, Clinical endocrinology.
[41] Miklós Tóth,et al. The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. , 2011, European journal of endocrinology.
[42] E. Papini,et al. AME position statement on adrenal incidentaloma. , 2011, European journal of endocrinology.
[43] J. Jørgensen,et al. Epidemiology of Cushing’s Syndrome , 2010, Neuroendocrinology.
[44] J. Mullins,et al. Mineralocorticoid and Glucocorticoid Receptors Stimulate Epithelial Sodium Channel Activity in a Mouse Model of Cushing Syndrome , 2009, Hypertension.
[45] Q. Duh,et al. Waiting for change: symptom resolution after adrenalectomy for Cushing's syndrome. , 2008, Surgery.
[46] V. Montori,et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. , 2008, The Journal of clinical endocrinology and metabolism.
[47] Charles B. Wilson,et al. Transsphenoidal microsurgery for Cushing's disease: initial outcome and long-term results. , 2004, The Journal of clinical endocrinology and metabolism.
[48] M. Quinkler,et al. Hypertension and the cortisol-cortisone shuttle. , 2003, The Journal of clinical endocrinology and metabolism.
[49] C Hagen,et al. Incidence and late prognosis of cushing's syndrome: a population-based study. , 2001, The Journal of clinical endocrinology and metabolism.
[50] L. del Viscovo,et al. Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features. , 2000, The Journal of clinical endocrinology and metabolism.
[51] A. Klibanski,et al. Long-term mortality after transsphenoidal surgery for Cushing disease. , 1999 .
[52] B. Walker,et al. 11 beta-Hydroxysteroid dehydrogenase activity in Cushing's syndrome: explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome. , 1995, The Journal of clinical endocrinology and metabolism.
[53] J. Norton,et al. Time to recovery of the hypothalamic-pituitary-adrenal axis after curative resection of adrenal tumors in patients with Cushing's syndrome. , 1990, Surgery.